Scholarlink

Background <p>Whole Transcriptome Sequencing (WTS) is a comprehensive alternative to targeted panels for detecting gene fusions and splice variants. To integrate WTS into clinical diagnostics, we compared its performance against established fusion assays (Archer FusionPlex and TSO500 RNA).</p> Methods <p>WTS was evaluated in an initial cohort of 64 FFPE tumor samples, and quality control (QC) thresholds were defined based on missed fusions correlating with low tumor cell content (TCC &lt; 40%). Key QC metrics included TCC ≥ 40%, RNA input ≥50 ng, ≥50 million reads, and median insert size &gt;100 bp.</p> Results <p>WTS identified 92% of known fusions in the initial cohort. Validation in 357 samples showed 100% concordance with panel-based results when QC thresholds were met. Subsequent clinical deployment across 812 diverse tumor cases detected 121 fusions, though 423 (34%) required fallback to targeted assays due to low TCC. WTS provided added value by detecting novel fusions, pathogens, and enabling oncogenic pathway analysis.</p> Conclusion <p>WTS is a reliable and informative method for fusion and splice variant detection in clinical diagnostics, provided rigorous pre-analytical and sequencing QC metrics are strictly applied.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月14日

查看全文
  • Markus Ball,
  • Susanne Beck,
  • Darius Wlochowitz,
  • Tina Fuchs,
  • Katja Lorenz,
  • Christiane Zgorzelski,
  • Alejandro Pallares Robles,
  • Michael Allgäuer,
  • Anna-Lena Volckmar,
  • Hannah Goldschmid,
  • Iordanis Ourailidis,
  • Regine Brandt,
  • Petros Christopoulos,
  • Michael Thomas,
  • Huriye Seker-Cin,
  • Annette Fink,
  • Fabian Schnecko,
  • Olaf Neumann,
  • Michael Menzel,
  • Martina Kirchner,
  • Thoas Fioretos,
  • Peter Schirmacher,
  • Solange Peters,
  • Jan Budczies,
  • Albrecht Stenzinger,
  • Daniel Kazdal

摘要

Background

Whole Transcriptome Sequencing (WTS) is a comprehensive alternative to targeted panels for detecting gene fusions and splice variants. To integrate WTS into clinical diagnostics, we compared its performance against established fusion assays (Archer FusionPlex and TSO500 RNA).

Methods

WTS was evaluated in an initial cohort of 64 FFPE tumor samples, and quality control (QC) thresholds were defined based on missed fusions correlating with low tumor cell content (TCC < 40%). Key QC metrics included TCC ≥ 40%, RNA input ≥50 ng, ≥50 million reads, and median insert size >100 bp.

Results

WTS identified 92% of known fusions in the initial cohort. Validation in 357 samples showed 100% concordance with panel-based results when QC thresholds were met. Subsequent clinical deployment across 812 diverse tumor cases detected 121 fusions, though 423 (34%) required fallback to targeted assays due to low TCC. WTS provided added value by detecting novel fusions, pathogens, and enabling oncogenic pathway analysis.

Conclusion

WTS is a reliable and informative method for fusion and splice variant detection in clinical diagnostics, provided rigorous pre-analytical and sequencing QC metrics are strictly applied.